PledPharma publishes prospectus in connection with the list change to Nasdaq Stockholm’s main market

October 29, 2019

On October 16, 2019, PledPharma AB (publ) announced that Nasdaq Stockholm’s Listing Committee approved admission of the company’s shares for trading on Nasdaq Stockholm’s regulated market. The prospectus, prepared in connection with the list change, has today been approved and registered by the Swedish Financial Supervisory Authority and is now available on PledPharma's website, www.pledpharma.com.

First day of trading on Nasdaq Stockholm’s main market is scheduled for October 31, 2019 and the last day of trading on Nasdaq First North Growth Market is scheduled for October 30, 2019. The shares will be traded under the same ticker (PLED) and ISIN-code (SE0003815604). There is no fund raising or new share issue in connection with the list change, and shareholders in PledPharma do not need to take any actions.

Pareto Securities AB and Advokatfirman Lindahl KB are PledPharma’s financial and legal advisers respectively, in connection with the listing.

About Us

PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The company’s most advanced project PledOx® is being developed to reduce nerve damage associated with chemotherapy. A global phase III program is ongoing. The drug candidate Aladote® is being developed to reduce the risk of acute liver injury associated with paracetamol poisoning. A proof of principle study has been successfully completed and the design of the next study is being finalised. Aladote® has been granted Orphan Drug Designation in the US. PledPharma (STO: PLED) is listed on Nasdaq First North. Erik Penser Bank is the company’s Certified Adviser (tel +46 8 463 83 00, [email protected]). For more information, see http://www.pledpharma.com/

PledPharma publishes prospectus in connection with the list change to Nasdaq Stockholm’s main market

Contact us